Pfizer returns rindopepimut rights

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.25 (26%) to $3.53 on Friday after Pfizer Inc. (NYSE:PFE) terminated a 2008 deal and returned all rights to develop and commercialize rindopepimut ( CDX-110). According to Celldex, Pfizer said the glioblastoma multiforme (GBM) candidate was no longer a strategic priority. Celldex said it plans to continue development of the vaccine targeting EGFR variant III ( EGFRvIII), which is in Phase IIb testing. ...